Free Trial

Unity Biotechnology Q1 2024 Earnings Report

Unity Biotechnology logo
$0.96 -0.01 (-1.04%)
(As of 12/20/2024 05:40 PM ET)

Unity Biotechnology EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.57
Beat/Miss
Beat by +$0.23
One Year Ago EPS
N/A

Unity Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Unity Biotechnology Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Unity Biotechnology Earnings Headlines

Your bank is lying to you.
You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.
Unity Software: What Really Matters For Long-Term Growth
See More Unity Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Unity Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unity Biotechnology and other key companies, straight to your email.

About Unity Biotechnology

Unity Biotechnology (NASDAQ:UBX), a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

View Unity Biotechnology Profile

More Earnings Resources from MarketBeat

Upcoming Earnings